JP7701913B2 - 抗ｎｒｐ２抗体を含む組成物および方法 - Google Patents

抗ｎｒｐ２抗体を含む組成物および方法 Download PDF

Info

Publication number
JP7701913B2
JP7701913B2 JP2022520527A JP2022520527A JP7701913B2 JP 7701913 B2 JP7701913 B2 JP 7701913B2 JP 2022520527 A JP2022520527 A JP 2022520527A JP 2022520527 A JP2022520527 A JP 2022520527A JP 7701913 B2 JP7701913 B2 JP 7701913B2
Authority
JP
Japan
Prior art keywords
nrp2
antibody
antigen
domain
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551603A5 (enExample
JP2022551603A (ja
Inventor
ルーク バーマン，
イーティン チョン，
レスリー アン グリーン，
デイビッド キング，
ジウェン シュー，
ライアン アンドリュー アダムス，
Original Assignee
エータイアー ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エータイアー ファーマ， インコーポレイテッド filed Critical エータイアー ファーマ， インコーポレイテッド
Publication of JP2022551603A publication Critical patent/JP2022551603A/ja
Publication of JP2022551603A5 publication Critical patent/JP2022551603A5/ja
Priority to JP2025104875A priority Critical patent/JP2025126239A/ja
Application granted granted Critical
Publication of JP7701913B2 publication Critical patent/JP7701913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
JP2022520527A 2019-10-03 2020-10-02 抗ｎｒｐ２抗体を含む組成物および方法 Active JP7701913B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104875A JP2025126239A (ja) 2019-10-03 2025-06-20 抗ｎｒｐ２抗体を含む組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962910042P 2019-10-03 2019-10-03
US62/910,042 2019-10-03
US202063024960P 2020-05-14 2020-05-14
US63/024,960 2020-05-14
PCT/US2020/054017 WO2021067761A1 (en) 2019-10-03 2020-10-02 Compositions and methods comprising anti-nrp2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104875A Division JP2025126239A (ja) 2019-10-03 2025-06-20 抗ｎｒｐ２抗体を含む組成物および方法

Publications (3)

Publication Number Publication Date
JP2022551603A JP2022551603A (ja) 2022-12-12
JP2022551603A5 JP2022551603A5 (enExample) 2023-09-28
JP7701913B2 true JP7701913B2 (ja) 2025-07-02

Family

ID=75338623

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520527A Active JP7701913B2 (ja) 2019-10-03 2020-10-02 抗ｎｒｐ２抗体を含む組成物および方法
JP2025104875A Pending JP2025126239A (ja) 2019-10-03 2025-06-20 抗ｎｒｐ２抗体を含む組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104875A Pending JP2025126239A (ja) 2019-10-03 2025-06-20 抗ｎｒｐ２抗体を含む組成物および方法

Country Status (7)

Country Link
US (3) US11807687B2 (enExample)
EP (1) EP4037711A4 (enExample)
JP (2) JP7701913B2 (enExample)
CN (1) CN114746120B (enExample)
AU (1) AU2020358854B2 (enExample)
CA (1) CA3156803A1 (enExample)
WO (1) WO2021067761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
AU2022375785A1 (en) * 2021-10-27 2024-04-11 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
WO2023164610A2 (en) * 2022-02-25 2023-08-31 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2b antibodies
WO2023164689A2 (en) * 2022-02-28 2023-08-31 University Of Massachusetts Targeting neuropilin 2 (nrp2) in lethal prostate cancer
WO2023245117A2 (en) * 2022-06-17 2023-12-21 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN122398809A (zh) * 2026-06-22 2026-07-17 四川大学华西医院 一种抗猫传染性腹膜炎病毒的药物组合、制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527350A (ja) 2007-05-17 2010-08-12 ジェネンテック， インコーポレイテッド 抗ニューロピリン２抗体による腫瘍転移の阻害
JP2012500832A (ja) 2008-08-27 2012-01-12 ダイアクローン 癌の治療のためのニューロピリン−２の中和によるｐ５３発現の誘導

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US6428965B1 (en) 1997-07-17 2002-08-06 The Johns Hopkins University Screening assays for the interaction of semaphorins and neuropilins
WO1999029858A1 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
CA2313607A1 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Antagonists of neuropilin receptor function and use thereof
WO1999029861A1 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
CN1313873A (zh) 1998-07-13 2001-09-19 表达遗传学公司 作为可溶性,生物可降解基因送递载体的聚－l－赖氨酸的聚酯类似物
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP1266014A2 (en) 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1519956B1 (en) 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004017945A1 (en) 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticles for dna administration to a target organ
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
US20090017023A1 (en) 2002-08-14 2009-01-15 Macrogenics, Inc. FcGammaRIIB Specific Antibodies and Methods of Use Thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
UA89348C2 (ru) 2002-10-16 2010-01-25 Евро-Селтик С.А. Изолированное моноклональное антитело, которое связывает клеточно-ассоциированный полипептид са 125/о772р
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
DE602004027291D1 (de) * 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
WO2006001888A2 (en) 2004-04-16 2006-01-05 Acuity Pharmaceuticals Inc Compositions and methods for inhibiting angiogenesis
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1951336A2 (en) 2005-07-18 2008-08-06 The Trustees Of Boston University Method to inhibit proliferation and growth of metastases
EP1915170A1 (en) 2005-08-16 2008-04-30 Klinikum der Universität Regensburg Use of neuropilin-2 antagonists
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
DK1945665T3 (da) 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
JP5242382B2 (ja) 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
EP2064335A4 (en) 2006-10-16 2011-03-30 Medimmune Llc MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
WO2008114011A2 (en) 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
ES2541051T3 (es) 2007-05-17 2015-07-15 Genentech, Inc. Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
US10457719B2 (en) 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2303293A1 (en) 2008-05-27 2011-04-06 Pluristem Ltd. Methods of treating inflammatory colon diseases
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
ES2602459T3 (es) * 2008-12-26 2017-02-21 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-CD4
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5730280B2 (ja) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド 非カノニカル生物学的活性を有するヒスチジル−ｔＲＮＡシンテターゼスプライスバリアントを含む組成物および方法
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
RU2012114094A (ru) 2009-09-11 2013-10-20 Дженентек, Инк. Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
PH12012500564A1 (en) 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
CN102667484A (zh) 2009-10-13 2012-09-12 约翰·霍普金斯大学 识别黑素瘤肿瘤细胞的生物标记
US8871509B2 (en) 2009-11-06 2014-10-28 Chung-Ang University-Academy Corporation Foundation Nanoparticle-based gene delivery systems
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP2796467B1 (en) * 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
WO2012091523A2 (en) 2010-12-30 2012-07-05 Samyang Biopharmaceuticals Corporation Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
EP2700652B1 (en) 2011-04-18 2018-12-19 The University of Tokyo Diagnosis and treatment of cancer using anti-itm2a antibody
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
KR101383324B1 (ko) 2011-11-10 2014-04-28 주식회사 종근당 신규한 유전자 전달용 조성물
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
WO2013116742A1 (en) 2012-02-01 2013-08-08 Mayo Foundation For Medical Education And Research Predicting responses to androgen deprivation therapy and methods for treating prostate cancer
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
JP6261617B2 (ja) 2013-02-14 2018-01-17 ユーシーエル ビジネス ピーエルシー 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
JP2016515120A (ja) * 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
JP6427789B2 (ja) 2013-07-23 2018-11-28 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
WO2015095686A1 (en) 2013-12-20 2015-06-25 Trustees Of Boston University Assays and methods relating to the treatment of melanoma
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP2017518307A (ja) 2014-06-02 2017-07-06 チルドレンズ メディカル センター コーポレーション 免疫調節のための方法および組成物
MX2017001946A (es) 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
US11104724B2 (en) 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
TW201825118A (zh) * 2016-11-30 2018-07-16 美商艾堤爾製藥公司 抗-hrs抗體及用於治療癌症之組合療法
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
CN111801353B (zh) * 2017-10-13 2024-09-17 A&G药品公司 针对前列腺素f2受体抑制剂的单克隆抗体和缀合物及其用途
US12365916B2 (en) 2017-10-30 2025-07-22 Miltenyi Biotec B.V. & Co. KG Adapter-based retroviral vector system for the selective transduction of target cells
BR112020015006A2 (pt) 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
WO2019195770A1 (en) * 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MX2021011489A (es) 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
ES3049416T3 (en) 2019-09-23 2025-12-16 Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P Antibodies for the diagnosis and/or treatment of atherosclerosis
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2021202590A1 (en) 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
JP7705674B2 (ja) 2021-10-15 2025-07-10 学校法人 芝浦工業大学 イメージセンサデータ制御システム
AU2022375785A1 (en) 2021-10-27 2024-04-11 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
WO2023245117A2 (en) 2022-06-17 2023-12-21 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527350A (ja) 2007-05-17 2010-08-12 ジェネンテック， インコーポレイテッド 抗ニューロピリン２抗体による腫瘍転移の阻害
JP2012500832A (ja) 2008-08-27 2012-01-12 ダイアクローン 癌の治療のためのニューロピリン−２の中和によるｐ５３発現の誘導

Also Published As

Publication number Publication date
EP4037711A1 (en) 2022-08-10
US20260092122A1 (en) 2026-04-02
US11807687B2 (en) 2023-11-07
CA3156803A1 (en) 2021-04-08
WO2021067761A1 (en) 2021-04-08
CN114746120B (zh) 2024-07-30
US12410253B2 (en) 2025-09-09
US20240092917A1 (en) 2024-03-21
US20210163606A1 (en) 2021-06-03
AU2020358854B2 (en) 2026-08-13
AU2020358854A1 (en) 2022-05-26
JP2025126239A (ja) 2025-08-28
CN114746120A (zh) 2022-07-12
JP2022551603A (ja) 2022-12-12
EP4037711A4 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
US12065495B2 (en) Compositions and methods comprising anti-NRP2 antibodies
US12410253B2 (en) Compositions comprising anti-NRP2 antibodies
US20180282402A1 (en) Anti-hrs antibodies and combinaton therapies for treating cancers
US20240417476A1 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN120858108A (zh) 抗il-18bp抗体
WO2021257808A2 (en) Antibodies to fibroblast activation protein and b7h3
US20250188170A1 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES
CA3205839A1 (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250620

R150 Certificate of patent or registration of utility model

Ref document number: 7701913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150